ChiCTR2300069836 版本V1.0 版本创建时间2023/03/27 15:03:55 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300069836 

最近更新日期:

Date of Last Refreshed on:

2023-03-27 15:03:38 

注册时间:

Date of Registration:

2023-03-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

无阿片类药物与基于阿片类药物的麻醉对老年患者在单侧膝关节置换术后免疫功能的影响

Public title:

Effects of opioid-free and opioid-based anesthesia on immune function in elderly patients after unilateral knee arthroplasty

注册题目简写:

English Acronym:

研究课题的正式科学名称:

无阿片类药物与基于阿片类药物的麻醉对老年患者在单侧膝关节置换术后免疫功能的影响

Scientific title:

Effects of opioid-free and opioid-based anesthesia on immune function in elderly patients after unilateral knee arthroplasty

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

韩紫芯 

研究负责人:

倪超波 

Applicant:

Zixin Han 

Study leader:

Chaobo Ni 

申请注册联系人电话:

Applicant telephone:

18361268132

研究负责人电话:

Study leader's
telephone:

13758070124

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hanzixin1997@163.com

研究负责人电子邮件:

Study leader's E-mail:

jxnichaobo@zjxu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

嘉兴市第一医院

研究负责人通讯地址:

嘉兴市第一医院

Applicant address:

The Affiliated Hospital of Jiaxing University, Jiaxing, China

Study leader's address:

The Affiliated Hospital of Jiaxing University, Jiaxing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

嘉兴市第一医院

Applicant's institution:

The Affiliated Hospital of Jiaxing University, Jiaxing, China

研究负责人所在单位:

嘉兴市第一医院

Affiliation of the Leader:

The Affiliated Hospital of Jiaxing University, Jiaxing, China

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023-KY-092

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

嘉兴市第一医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the Affiliated Hospital of Jiaxing University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-03-24 00:00:00

伦理委员会联系人:

钱建萍

Contact Name of the ethic committee:

Jianping Qian

伦理委员会联系地址:

浙江省嘉兴市南湖区城南街道中环南路1882号

Contact Address of the ethic committee:

1882 Zhonghuan South Road, Chengnan Street, Nanhu District, Jiaxing, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 573 89976378

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

嘉兴市第一医院

Primary sponsor:

The Affiliated Hospital of Jiaxing University, Jiaxing, China

研究实施负责(组长)单位地址:

浙江省嘉兴市南湖区城南街道中环南路1882号

Primary sponsor's address:

1882 Zhonghuan South Road, Chengnan Street, Nanhu District, Jiaxing, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

嘉兴

Country:

China

Province:

Zhejiang

City:

Jiaxing

单位(医院):

嘉兴市第一医院

具体地址:

浙江省嘉兴市南湖区城南街道中环南路1882号

Institution
hospital:

The Affiliated Hospital of Jiaxing University, Jiaxing, China

Address:

1882 Zhonghuan South Road, Nanhu District, Jiaxing, Zhejiang

经费或物资来源:

嘉兴市第一医院

Source(s) of funding:

The Affiliated Hospital of Jiaxing University, Jiaxing, China

研究疾病:

膝关节置换术围手术期管理  

Target disease:

Perioperative management of knee arthroplasty

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探究OFA在老年膝关节置换术中的潜在益处。减少阿片类麻醉药的使用,从而减轻阿片类药物的副作用。促进患者术后康复,提高患者术中术后舒适度,从而指导老年患者单侧膝关节置换术的临床麻醉工作。  

Objectives of Study:

To explore the potential benefits of OFA in elderly knee arthroplasty. Reduce the use of opioid anesthetics, thereby reducing the side effects of opioids. To promote the postoperative rehabilitation of patients, improve the comfort of patients during and after operation, so as to guide the clinical anesthesia of unilateral knee arthroplasty in elderly patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1) 参与中心收治的老年患者,年龄范围:60周岁至80周岁;2)接受单侧膝关节置换手术;3) 签署知情同意书;4) BMI: 20-30 kg/m2;5) ASA I-III级。

Inclusion criteria

1 ) Elderly patients admitted to the participating center, age range : 60 to 80 years old ; 2 ) unilateral knee arthroplasty ; 3 ) Sign informed consent ; 4 ) BMI : 20-30 kg / m2 ; 5 ) ASA I-III.

排除标准:

1) 对用于麻醉的药物或其辅料的过敏;2) 心房室传导阻滞、脑室内或窦房传导阻滞;3) Adam-Stokes综合症;4) 长期接受β-阻滞剂和HR<50次/分;5) 严重的心血管疾病(如心绞痛和心肌梗死);6) 眼内压高;7) 甲状腺功能亢进;8) 神经阻滞禁忌症;9) 长期镇痛药物应用史;10) 患有精神疾病或无法正常交流。

Exclusion criteria:

1 ) Allergic to drugs or their excipients for anesthesia ; 2 ) atrioventricular block, intraventricular or sinus atrial block ; 3 ) Adam-Stokes syndrome ; 4 ) long-term acceptance of β-blockers and HR < 50 times / min ; 5 ) severe cardiovascular diseases ( such as angina and myocardial infarction ) ; 6 ) High intraocular pressure ; 7 ) hyperthyroidism ; 8 ) nerve block contraindications ; 9 ) long-term analgesic drug application history ; 10 ) suffering from mental illness or unable to communicate normally.

研究实施时间:

Study execute time:

From 2023-04-01 00:00:00 To 2025-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-01 00:00:00 To 2025-04-30 00:00:00

干预措施:

Interventions:

组别:

OFA组

样本量:

30

Group:

OFA group

Sample size:

干预措施:

麻醉诱导:丙泊酚1.5-2 mg/kg,利多卡因1-1.5 mg/kg,艾司氯胺酮0.2-0.5 mg/kg和顺式阿曲库铵 0.15 mg/kg; 麻醉维持:艾司氯胺酮0.1-0.5 mg/(kg.h)、右美托咪定0.4-1.4 ug/(kg.h)、利多卡因1 mg/(kg.h)和七氟烷。

干预措施代码:

Intervention:

Anesthesia induction: Propofol 1.5-2 mg/kg, Lidocaine 1-1.5 mg/kg, Esketamine 0.2-0.5 mg/kg, and Cisatracurium 0.15 mg/kg; Anesthesia maintenance: Esketamine 0.1-0.5 mg/(kg·h), Dexmedetomidine 0.4-1.4 μg/(kg·h), Lidocaine 1 mg/(kg·h), and Sevoflurane.

Intervention code:

组别:

OBA组

样本量:

30

Group:

OBA group

Sample size:

干预措施:

麻醉诱导:丙泊酚1.5-2 mg/kg,利多卡因1-1.5 mg/kg,舒芬太尼0.1-0.5 ug/kg和顺式阿曲库铵 0.15 mg/kg; 麻醉维持:瑞芬太尼8-10 ug/(kg.h)、右美托咪定0.4-1.4 ug/(kg.h)、利多卡因1 mg/(kg.h)和七氟烷。

干预措施代码:

Intervention:

Anesthesia induction: Propofol 1.5-2 mg/kg, Lidocaine 1-1.5 mg/kg, Sufentanil 0.1-0.5 μg/kg, and Cisatracurium 0.15 mg/kg; Anesthesia maintenance: Remifentanil 8-10 μg/(kg·h), Dexmedetomidine 0.4-1.4 μg/(kg·h), Lidocaine 1 mg/(kg·h), and Sevoflurane.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

嘉兴 

Country:

China

Province:

Zhejiang

City:

Jiaxing

单位(医院):

嘉兴市第一医院 

单位级别:

三甲 

Institution
hospital:

Jiaxing First Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疼痛视觉模拟评分

指标类型:

次要指标

Outcome:

visual analogue scale, VAS

Type:

Secondary indicator

测量时间点:

术前及术后4 h、8 h、12h、24 h、48 h和72 h

测量方法:

静止状态和被动屈膝60°

Measure time point of outcome:

Preoperative and postoperative 4 h, 8 h, 12 h, 24 h, 48 h and 72 h

Measure method:

Static state and passive knee flexion at 60°

指标中文名:

主动屈膝最大角度和步行距离

指标类型:

次要指标

Outcome:

Active knee flexion maximum angle and walking distance

Type:

Secondary indicator

测量时间点:

术后48h和72h

测量方法:

随访

Measure time point of outcome:

Postoperative 48 h and 72 h

Measure method:

follow-up

指标中文名:

NK细胞占总淋巴细胞比例

指标类型:

主要指标

Outcome:

The proportion of NK cells in total lymphocytes

Type:

Primary indicator

测量时间点:

术前1天和术后3天

测量方法:

流式细胞术

Measure time point of outcome:

Preoperative day 1 and postoperative day 3.

Measure method:

flow cytometry

指标中文名:

CD3+细胞占总淋巴细胞比例

指标类型:

次要指标

Outcome:

The proportion of CD3+ cells in total lymphocytes

Type:

Secondary indicator

测量时间点:

术前1天和术后3天

测量方法:

流式细胞术

Measure time point of outcome:

Preoperative day 1 and postoperative day 3.

Measure method:

flow cytometry

指标中文名:

CD4+细胞占总淋巴细胞比例

指标类型:

次要指标

Outcome:

The proportion of CD4+ cells in total lymphocytes

Type:

Secondary indicator

测量时间点:

术前1天和术后3天

测量方法:

流式细胞术

Measure time point of outcome:

Preoperative day 1 and postoperative day 3.

Measure method:

flow cytometry

指标中文名:

CD8+细胞占总淋巴细胞比例

指标类型:

次要指标

Outcome:

The proportion of CD8+ cells in total lymphocytes

Type:

Secondary indicator

测量时间点:

术前1天和术后3天

测量方法:

流式细胞术

Measure time point of outcome:

Preoperative day 1 and postoperative day 3.

Measure method:

flow cytometry

指标中文名:

PCIA有效按压次数

指标类型:

次要指标

Outcome:

Number of effective compressions in PCIA

Type:

Secondary indicator

测量时间点:

术后4 h、8 h、12h、24 h、48 h和72 h

测量方法:

随访

Measure time point of outcome:

Postoperative 4 h, 8 h, 12 h, 24 h, 48 h and 72 h

Measure method:

follow-up

指标中文名:

阿片类药物消耗量

指标类型:

次要指标

Outcome:

Opioid consumption

Type:

Secondary indicator

测量时间点:

术后72 h

测量方法:

随访

Measure time point of outcome:

Postoperative 72 h

Measure method:

follow-up

指标中文名:

平均动脉压

指标类型:

次要指标

Outcome:

Mean arterial pressure

Type:

Secondary indicator

测量时间点:

术前、麻醉诱导、手术切皮、手术30分钟、手术结束

测量方法:

Measure time point of outcome:

Preoperative, induction of anesthesia, surgical skin incision, 30 minutes into the operation, end of the operation

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

Heart rate

Type:

Secondary indicator

测量时间点:

术前、麻醉诱导、手术切皮、手术30分钟、手术结束

测量方法:

Measure time point of outcome:

Preoperative, induction of anesthesia, surgical skin incision, 30 minutes into the operation, end of the operation

Measure method:

指标中文名:

脑电双频指数

指标类型:

次要指标

Outcome:

Bispectral Index, BIS

Type:

Secondary indicator

测量时间点:

术前、麻醉诱导、手术切皮、手术30分钟、手术结束

测量方法:

Measure time point of outcome:

Preoperative, induction of anesthesia, surgical skin incision, 30 minutes into the operation, end of the operation

Measure method:

指标中文名:

血管活性药物用量

指标类型:

次要指标

Outcome:

Dosage of vasoactive drugs

Type:

Secondary indicator

测量时间点:

手术结束

测量方法:

Measure time point of outcome:

End of the operation

Measure method:

指标中文名:

局麻药物中毒情况

指标类型:

次要指标

Outcome:

Local anesthetic poisoning situation

Type:

Secondary indicator

测量时间点:

手术结束

测量方法:

Measure time point of outcome:

End of the operation

Measure method:

指标中文名:

气管插管拔管时间

指标类型:

次要指标

Outcome:

Time of endotracheal tube extubation

Type:

Secondary indicator

测量时间点:

从停止麻醉至气管拔管

测量方法:

Measure time point of outcome:

From end of anesthetics to tracheal extubation

Measure method:

指标中文名:

术后恶心呕吐发生率

指标类型:

次要指标

Outcome:

Incidence rate of postoperative nausea and vomiting

Type:

Secondary indicator

测量时间点:

术后24小时

测量方法:

Measure time point of outcome:

Postoperative 24 h

Measure method:

指标中文名:

匹兹堡睡眠质量指数

指标类型:

次要指标

Outcome:

Pittsburgh sleep quality index,PSQI

Type:

Secondary indicator

测量时间点:

术后第3天

测量方法:

Measure time point of outcome:

Postoperative day 3

Measure method:

指标中文名:

补救镇痛

指标类型:

次要指标

Outcome:

Rescue analgesia

Type:

Secondary indicator

测量时间点:

术后72h

测量方法:

Measure time point of outcome:

Postoperative 72 h

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

Length of hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

B淋巴细胞占总淋巴细胞比例

指标类型:

次要指标

Outcome:

The proportion of B lymphocytes in total lymphocytes

Type:

Secondary indicator

测量时间点:

术前1天和术后3天

测量方法:

流式细胞术

Measure time point of outcome:

Preoperative day 1 and postoperative day 3.

Measure method:

flow cytometry

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

静脉

Sample Name:

blood

Tissue:

vein

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

stata生成随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

stata generates a random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国知网,http://www.cnki.net/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.cnki.net/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

海泰电子病例系统3.0,EXCEL统一记录上传

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data are collected by Heitai Electronic Medical Record System 3.0,then use EXCELto record data and upload.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2023-03-27 15:03:38